Management of thyroid eye disease

European Journal of Nuclear Medicine

Volumn 29, Issue SUPPL. 2, 2002, Pages

  Bartalena, Luigi ^a,b   Marcocci, Claudio ^a,b   Tanda, Maria ^a,b   Pinchera, Aldo ^a,b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Cigarette Smoking; Graves' Ophthalmopathy; Hyperthyroidism; Thyroid eye disease; Treatment

Indexed keywords

AZATHIOPRINE; CIAMEXON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RADIOACTIVE IODINE; SOMATOSTATIN DERIVATIVE; THIONAMIDE; ANGIOPEPTIN; ANTITHYROID AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; EYE DROPS; OCTREOTIDE; SOMATOSTATIN;

CIGARETTE SMOKING; DECOMPRESSION SURGERY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; EYE DISEASE; GRAVES DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OINTMENT; ORBIT DISEASE; PLASMAPHERESIS; PRISM; REVIEW; RISK FACTOR; SPECTACLES; THYROID DISEASE; THYROIDECTOMY; TREATMENT OUTCOME; DIPLOPIA; EXTRAOCULAR MUSCLE; EYE PROTECTIVE DEVICE; EYELID; MULTIMODALITY CANCER THERAPY; OPTIC NERVE DISEASE; PHOTOPHOBIA; SMOKING CESSATION;

ANTITHYROID AGENTS; COMBINED MODALITY THERAPY; DECOMPRESSION, SURGICAL; DIPLOPIA; EYE PROTECTIVE DEVICES; EYELIDS; GLUCOCORTICOIDS; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IODINE RADIOISOTOPES; OCTREOTIDE; OCULOMOTOR MUSCLES; OINTMENTS; OPHTHALMIC SOLUTIONS; OPTIC NERVE DISEASES; PEPTIDES, CYCLIC; PHOTOPHOBIA; PLASMAPHERESIS; SMOKING CESSATION; SOMATOSTATIN; THYROIDECTOMY;

EID: 0036360667     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0813-6     Document Type: Review

References (67)

1. Management of Graves' ophthalmopathy: Reality and perspectives
2. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management
3. Pathogenesis of Graves' ophthalmopathy: Recent controversies and progress
4. Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured retro-ocular fibroblasts
5. Modulation of orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists
6. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture
7. Has the autoantigen for Graves' ophthalmopathy been found?
8. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach
9. Classification of eye changes of Graves' disease
10. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey
11. Treating severe Graves' ophthalmopathy
12. Glucocorticoid therapy of Graves' ophthalmopathy
13. Graves' ophthalmopathy
14. Dexamethasone regulation of glycosaminoglycan synthesis in cultured human fibroblasts: Similar effects of glucocorticoid and thyroid hormone therapy
15. Comparison of the effectiveness and tolerability of intravenous and oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study
16. Radiotherapy of Graves' ophthalmopathy
17. Orbital radiotherapy for Graves' ophthalmopathy
18. Immunosuppressant therapy of thyroid eye disease
19. Graves' ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids
20. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: A randomized, single blind trial
21. Prognostic factors in the radiotherapy of Graves' ophthalmopathy
22. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: Comparison with systemic corticosteroids alone
23. Radiation retinopathy after standard radiotherapy for thyroid-related ophthalmopathy
24. Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy
25. Radiotherapy for Graves' orbitopathy: Randomised placebo-controlled study
26. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy
27. Radiation therapy for Graves' ophthalmopathy: Trick or treat?
28. Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
29. Orbital radiotherapy combined with high-dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than orbital radiotherapy alone: Results of a prospective study
30. Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy
31. Current trends in orbital decompression
32. Surgical treatment of thyroid eye disease
33. Cyclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: A controlled, randomized and prospective study
34. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy
35. Immunosuppressive therapy in patients with thyroid eye disease: An overview of current concepts
36. Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis
37. Studies on the occurrence of ophthalmopathy in Graves' disease
38. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism
39. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy
40. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment
41. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism
42. Current trends in the management of Graves' disease
43. Radioiodine therapy does not aggravate Graves' ophthalmopathy
44. Radioiodine may be bad for Graves' ophthalmopathy, but..
45. Radioiodine and thyroid-associated ophthalmopathy
46. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism
47. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: A case-control study
48. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?
49. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?
50. Treatment of hyperthyroidism
51. The genetic susceptibility to Graves' disease
52. Graves' ophthalmopathy: A preventable disease?
53. Cigarette smoking and the thyroid
54. Cigarette smoking and the thyroid
55. Smoking and risk of Graves' disease
56. More on smoking habits and Graves' ophthalmopathy
57. Smoking and endocrine ophthalmopathy: Impact of smoking severity and current vs lifetime cigarette consumption
58. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy
59. Effects of smoking on thyroid function
60. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: Possible role in thyroid-associated ophthalmopathy
61. Hypoxia/reoxygenation stimulates endothelial cells to promote interleukin-1 and interleukin-6 production. Effects of free radical scavengers
62. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves' ophthalmopathy undergoing orbital radiotherapy
63. Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids
64. Rheumatoid arthritis: Anticytokine therapies on the horizon
65. Beneficial effect of pentoxyfilline on thyroid-associated ophthalmopathy
66. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: Measurement by the Medical Outcomes Study Instrument
67. Long-term follow-up of Graves ophthalmopathy in an incidence cohort